Good day, everyone and welcome to the graphic packaging third quarter, 2024 earnings call. At this time, all participants have been placed on a listen-only mode and we will open the floor for your ...
Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.